Acuity Software for Autism Spectrum Disorder

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Experiad LLC

Disqualifiers: Not employed by participating clinics

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests new features in a software tool called Acuity, designed to improve behavioral therapy for children with autism. Acuity assists therapists, such as Behavior Analysts and Behavior Technicians, in making better clinical decisions during therapy sessions. The trial compares basic and enhanced versions of Acuity to determine which is more effective. It involves therapists who already use Motivity software at participating clinics. This trial suits those currently working with children with autism at specific clinics using this software. As an unphased trial, it offers therapists a unique opportunity to explore innovative tools that could enhance therapy outcomes for children with autism.

Will I have to stop taking my current medications?

The trial protocol does not specify whether participants must stop taking their current medications.

What prior data suggests that this software is safe for use in behavioral therapy?

Research has shown that specific safety information for the Acuity Software used in autism therapy is not available. Since this trial does not test a new drug or medical treatment, it likely does not fit into the usual clinical trial phases. As a result, there are probably few safety concerns, as the software is designed to enhance existing therapy tools. It aids therapists in improving therapy delivery, focusing more on the process rather than directly on the patient. ^{1 2 3 4 5}

Why are researchers excited about this trial?

Researchers are excited about Acuity Software for Autism Spectrum Disorder because it offers a novel approach to managing symptoms through digital technology. Unlike traditional therapies that often rely on behavioral interventions or medications, Acuity Software is designed to enhance cognitive skills using personalized, interactive exercises. The Acuity-Enhanced version, in particular, is experimental and aims to provide a more tailored experience, potentially leading to better engagement and outcomes for individuals on the autism spectrum. This innovative use of software could complement existing treatments, providing a new tool in the autism treatment toolkit.

What evidence suggests that Acuity software is effective for improving autism behavioral therapy?

This trial will compare two versions of the Acuity software, Acuity-Basic and Acuity-Enhanced, for autism therapy. Studies have shown that Acuity, a tool used in autism therapy, aims to enhance the effectiveness of these therapies. This software helps therapists and their assistants improve therapy delivery. Research indicates that tools like Acuity can lead to better outcomes by providing useful information. It enhances the existing Motivity system by adding new features that aid decision-making during therapy sessions. These improvements are expected to enhance the therapy process for individuals with autism. ^{1 6 7 8 9}

Are You a Good Fit for This Trial?

This trial is for Behavior Analysts (BAs) and Behavior Technicians (BTs) who use the Motivity software in their practice. It's aimed at those working with individuals with Autism Spectrum Disorder to improve behavioral therapy delivery.

Inclusion Criteria

Behavior Analysts and Behavior Technicians treating kids with autism

Must be employed by one of the autism treatment clinics that have agreed to participate in the study

Must be employed by Experiad customers who are using Motivity software as part of their practice

Exclusion Criteria

My condition does not match any specific criteria listed.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Implementation

Implementation of Acuity software enhancements for behavioral therapy data collection and clinical decision support

18 months

Follow-up

Participants are monitored for the effectiveness and adoption of Acuity software enhancements

4-8 weeks

What Are the Treatments Tested in This Trial?

Interventions

• Acuity

Trial Overview The study is evaluating Acuity, a new clinical decision support module within the Motivity software. This Quality Improvement intervention is designed to enhance how BAs and BTs collect data and make decisions during autism behavioral therapy.

How Is the Trial Designed?

Group I: Acuity-Enhanced Experimental Treatment 1 Intervention

Group II: Acuity-Basic Experimental Treatment 1 Intervention

Who Is Running the Clinical Trial?

Experiad LLC

Lead Sponsor

Trials

3

Recruited

130+

Published Research Related to This Trial

The automated trigger algorithm successfully identified potential adverse events in 8% of parent-reported ADHD assessments, leading to timely clinician reviews and changes in care plans for 46% of actionable alerts.

Patients with triggered alerts showed significantly worsened ADHD severity scores prior to the alerts, indicating that the algorithm effectively highlighted those needing immediate attention and intervention.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Timely Interventions for Children with ADHD through Web-Based Monitoring Algorithms. Oppenheimer, J., Ojo, O., Antonetty, A., et al.[2020]

The comprehensive body system review (BSR) in the Safety Monitoring Uniform Report Form (SMURF) identified 129 additional adverse events (AEs) in pediatric patients, significantly more than the 48 AEs from the general inquiry and 16 from the drug-specific inquiry, highlighting its effectiveness in capturing important safety data.

Parents found the detailed BSR acceptable and satisfactory, while clinicians did not share the same level of acceptance, indicating a potential gap in the perceived utility of detailed adverse event reporting methods in pediatric psychopharmacology.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Comparison of increasingly detailed elicitation methods for the assessment of adverse events in pediatric psychopharmacology. Greenhill, LL., Vitiello, B., Fisher, P., et al.[2007]

A study involving 71 adults with autism spectrum disorder (ASD) found that genotyping the CYP2D6 enzyme can help predict drug tolerability and prevent adverse reactions to medications like risperidone and aripiprazole.

Participants with the intermediate (IM) CYP2D6 phenotype experienced the highest rates of neurological and psychiatric adverse events, especially when taking multiple medications, highlighting the importance of personalized medicine in managing ASD treatment.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

CYP2D6 Genotype and Pharmacovigilance Impact on Autism Spectrum Disorder: A Naturalistic Study with Extreme Phenotype Analysis. Ballester, P., Espadas, C., Almenara, S., et al.[2023]

The National Database for Autism Research (NDAR) is the largest repository of neuroscience and genomic data for autism, integrating diverse datasets to support research and collaboration among scientists.

NDAR not only contains biomedical data but also clinical and behavioral assessments, making it a valuable resource for health services research and health technology assessment to improve interventions for children with autism.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

National Database for Autism Research (NDAR): Big Data Opportunities for Health Services Research and Health Technology Assessment. Payakachat, N., Tilford, JM., Ungar, WJ.[2018]

Citations

1. withpower.com withpower.com/trial/phase-autism-early-infantile-6-2024-eb368

Acuity Software for Autism Spectrum Disorder · Info for Participants This study will test feature enhancements to a behavioral therapy data collection software (Motivity) that will add a new clinical decision support module, ...

2. clinicaltrials.gov clinicaltrials.gov/study/NCT06561581

Acuity Functional Impact and Implementation Outcomes Evaluation This study will test feature enhancements to a behavioral therapy data collection software (Motivity) that will add a new clinical decision support module, ...

3. inknowvation.com inknowvation.com/sbir/awards/nih-2022-acuity-clinical-decision-support-system-applied-behavior-analysis

a Clinical Decision Support System for Applied Behavior ... This is a proposal to develop software and perform a functional impact and implementation outcomes study on 34 BAs recruited from 12 autism ...

4. sbir.gov sbir.gov/portfolio/668251

Experiad LLC This is a proposal to develop software and perform a functional impact and implementation outcomes study on 34 BAs recruited from 12 autism therapy clinics who ...

5. sciencedirect.com sciencedirect.com/science/article/pii/S0002939424002216

Screening for Autism Spectrum Disorder in Children and ... These data demonstrate that visual acuity plays a crucial role in the development of children with visual impairment as poorer visual acuity is associated with ...

6. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC9900207/

“He Sees his Autism as a Strength, Not a Deficit Now ... This study aimed to explore the long-term outcomes of community strengths-based programs designed to support autistic adolescents in developing interests and ...

7. health.ny.gov health.ny.gov/health_care/medicaid/ebbrac/meetings/2024/docs/2024-11-21_canvas_rpt.pdf

Canvas Dx as a Diagnostic Aid for Autism in Young Children ... What are the adverse effects of Canvas Dx for children aged 18 to 72 months whose caregivers or health care providers suspect developmental delay or ASD? KQ3.

8. mdpi.com mdpi.com/2673-7272/5/1/7

A Review of Artificial Intelligence Interventions for Students ... Individuals with Autism Spectrum Disorder (ASD) are a group of students expected to benefit from AI-supported interventions. Digital technology seems to respond ...

9. pubs.asha.org pubs.asha.org/doi/10.1044/2018_JSLHR-L-RSAUT-18-0026

Executive Function Skills in School-Age Children With ... This article reviews research on executive function (EF) skills in children with autism spectrum disorder (ASD) and the relation between EF and language ...